CytoDyn

CYDY

The current CytoDyn (CYDY) market capitalization is approximately $296.04M, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, CytoDyn's market cap fluctuates with changes in its share price and share count. Last updated: March 7, 2026 at 7:12 PM Eastern Time

In the most recently reported fiscal year, CytoDyn (CYDY) generated net income of $-0.21B, compared with $-0.18B in the prior fiscal year, representing a -19.47% year over year change. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions.

CytoDyn (CYDY) is currently scheduled to report its next earnings results on April 28, 2026. Earnings dates are subject to change and may be updated by the company with limited notice. Investors typically monitor upcoming earnings releases closely, as they can result in increased volatility depending on reported results, forward guidance, and management commentary. Last updated: March 7, 2026 at 7:12 PM Eastern Time

CytoDyn's (CYDY) earnings reports, including quarterly and annual financial statements, are available through the company's official regulatory filings with the U.S. Securities and Exchange Commission (SEC). On Gainify, you can access CytoDyn's full set of filings, including earnings releases, Form 10-Q, Form 10-K, and other disclosures, in one place: CytoDyn SEC Filings These filings provide detailed information on CytoDyn's financial performance and are considered the primary source of verified financial data for publicly traded companies.

CytoDyn (CYDY) does not currently pay a dividend. Over the last twelve months (LTM), the company paid $0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future.

Based on the latest available analyst coverage, CytoDyn (CYDY) currently carries a not available consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice.

Like other publicly traded stocks, CytoDyn (CYDY) shares are bought and sold on stock exchanges such as OTCPK and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for CytoDyn (CYDY) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add CYDY to your watchlist.

CytoDyn trades under the ticker symbol CYDY on the OTCPK stock exchange. The ticker CYDY is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

As of the most recently reported period, CytoDyn (CYDY) employs approximately 13 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: March 7, 2026 at 7:12 PM Eastern Time

CytoDyn (CYDY) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest CytoDyn (CYDY) stock peers based on overlapping products, services, and competitive dynamics:Heron Therapeutics (HRTX)Curis (CRIS)Exelixis (EXEL)Kyntra Bio (KYNB)AIM ImmunoTech (AIM)Geron (GERN)LadRx (LADX)GT Biopharma (GTBP)Lisata Therapeutics (LSTA)Inhibitor Therapeutics (INTI) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to CytoDyn.